Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts

Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2010-05, Vol.50 (9), p.1252-1255
Hauptverfasser:	Memoli, Matthew J, Hrabal, Rachel J, Hassantoufighi, Arash, Eichelberger, Maryna C, Taubenberger, Jeffery K
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Substitution - genetics Antiviral Agents - pharmacology Antiviral drugs Cyclopentanes - pharmacology Drug resistance Drug Resistance, Viral Drug therapy Female Guanidines - pharmacology Humans Immunocompromised Host Infectious diseases Influenza A Virus, H1N1 Subtype - drug effects Influenza A Virus, H1N1 Subtype - genetics Influenza A Virus, H1N1 Subtype - isolation & purification Influenza, Human - drug therapy Influenza, Human - virology Inhibitor drugs Male Middle Aged Molecular Sequence Data Mutation Mutation, Missense Oseltamivir - pharmacology Pandemics RNA, Viral - genetics Selection, Genetic Sequence Analysis, DNA Swine flu Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir.
ISSN:	1058-4838 1537-6591
DOI:	10.1086/651605